Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Presenter: Dr. Niclas Stiernholm, Chief Executive Officer

Date:  September 5, 2018

Time:  4:15 pm (Eastern Time)

Location:  Library (2nd floor)

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com 

Contact:

James Parsons

Chief Financial Officer

Trillium Therapeutics Inc.

416-595-0627 x232

james@trilliumtherapeutics.com

www.trilliumtherapeutics.com  

Investor and Media Relations:

Jessica Tieszen

Canale Communications for Trillium Therapeutics

619-849-5385

jessica@canalecomm.com

Trillium Therapeutics Inc. Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!